Randomized Phase III Study of I.V. Vinorelbine plus hormonotherapy versus hormonotherapy alone in hormone refractory prostate cancer (HRPC)

Reviewer: Walter Sall, MD
OncoLink
Ultima Vez Modificado: 31 de mayo del 2003

Translation for this article does not exist